The methods described here outline a procedure used to optogenetically reverse cocaine-induced plasticity in a behaviorally-relevant circuit in rats. Sustained low-frequency optical stimulation of thalamo-amygdala synapses induces long-term depression (LTD). In vivo optogenetically-induced LTD in cocaine-experienced rats resulted in the subsequent attenuation of cue-motivated drug seeking.
This protocol demonstrates the steps needed to use optogenetic tools to reverse cocaine-induced plasticity at thalamo-amygdala circuits to reduce subsequent cocaine seeking behaviors in the rat. In our research, we had found that when rats self-administer intravenous cocaine paired with an audiovisual cue, synapses formed at inputs from the medial geniculate nucleus of the thalamus (MGN) onto principal neurons of the lateral amygdala (LA) become stronger as the cue-cocaine association is learned. We hypothesized that reversal of the cocaine-induced plasticity at these synapses would reduce cue-motivated cocaine seeking behavior. In order to accomplish this type of neuromodulation in vivo, we wanted to induce synaptic long-term depression (LTD), which decreases the strength of MGN-LA synapses. To this end, we used optogenetics, which allows neuromodulation of brain circuits using light. The excitatory opsin oChiEF was expressed on presynaptic MGN terminals in the LA by infusing an AAV containing oChiEF into the MGN. Optical fibers were then implanted in the LA and 473 nm laser light was pulsed at a frequency of 1 Hz for 15 minutes to induce LTD and reverse cocaine induced plasticity. This manipulation produces a long-lasting reduction in the ability of cues associated with cocaine to induce drug seeking actions.
Substance abuse is a very serious public health issue in the U.S. and worldwide. Despite decades of intense research, there are very few effective therapeutic options1,2. A major setback to treatment is the fact that chronic drug use generates long-term associative memories between environmental cues and the drug itself. Re-exposure to drug-related cues drives physiological and behavioral responses that motivate continued drug use and relapse3. A novel therapeutic strategy is to enact memory-based treatments that aim to manipulate the circuits involved in regulating drug-cue associations. Recently, it was observed that synapses in the lateral amygdala (LA), specifically those arising from the medial geniculate nucleus (MGN) of the thalamus, are strengthened by repeated cue-associated cocaine self-administration, and that this potentiation can support cocaine seeking behavior4,5. Therefore, it was proposed that cue-induced reinstatement could be attenuated by reversing plasticity at MGN-LA synapses.
The ability to precisely target the synaptic plasticity of a specific brain circuit has been a major challenge to the field. Traditional pharmacological tools have had some success in decreasing relapse behaviors, but are limited by the inability to manipulate individual synapses. However, the recent development of in vivo optogenetics has provided the tools needed to overcome these limitations and control neural pathways with temporal and spatial precision6,7,8. By expressing light-sensitive opsins in a specific brain circuit, laser light can then be used to activate or inhibit the circuit. Frequency-dependent optical stimulation can be utilized to specifically manipulate the synaptic plasticity of the circuit in a behaving animal.
This manuscript outlines the procedure taken to manipulate the behaviorally-relevant MGN-LA circuit using in vivo optogenetics. First, the excitatory opsin oChIEF was expressed in the MGN and optical fibers were bilaterally implanted in the LA. Animals were then trained to self-administer cocaine in a cue-dependent fashion, which potentiates the MGN-LA pathway. Next, sustained, low frequency stimulation with 473 nm laser light was used to produce circuit-specific LTD. Reversing the plasticity induced by cocaine use generated a long-lasting reduction in the capacity of cues to trigger actions that are associated with drug seeking behavior.
The experiments described in this protocol were consistent with the guidelines set forth by the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the University of Pittsburgh's Institutional Animal Care and Use Committee. All procedures were performed using adult, naïve Sprague-Dawley rats that weighed 275-325 g upon arrival.
1. Construction of Optic Fiber Implants and Patch Cables
2. Rodent Intravenous Catheterization, Virus Delivery, and Optic Fiber Implantation
3. Rodent Cocaine Self-Administration and Instrumental Lever Extinction
NOTE: All behavioral procedures are conducted in standard operant conditioning chambers, equipped with two retractable levers on one wall, a stimulus light above each lever, a tone generator, a house light, and an infusion pump.
4. In vivo Optogenetic Induction of LTD
NOTE: Optogenetic inhibition experiments take place 24 h after the final day of instrumental extinction.
5. Test the Effect of Optogenetic Stimulation on Cue-Induced Cocaine Seeking
6. Staining, Fluorescence, and Imaging for Histological Verification of Viral Expression and Optic Fiber Placement
7. Perfusion and Acute Brain Slice Preparation for Electrophysiology Experiments
NOTE: Electrophysiological experiments are performed on a subset of animals to validate the success of in vivo LTD.
8. Ex vivo Electrophysiological Recordings
A timeline outlining the order of experiments is shown in Figure 1. Throughout behavioral experiments, the number of cocaine infusions as well as the number of responses made on the active lever serves as a measure of the intensity of cocaine-seeking behavior. During the initial days of cocaine self-administration, the number of active responses should gradually increase across each acquisition day, before stabilizing during the second week. Conversely, inactive lever responses should remain low throughout the entirety of the experiment (Figure 2A). On the first day of instrumental extinction, there is typically an increase in the number of active lever responses, as the unexpected absence of cocaine results in the escalation of cocaine-seeking behavior. However, this response will gradually decrease with subsequent sessions as rats learn the new contingency, resulting in a low and stable number of active lever responses within 6-10 d (Figure 2B). Rats that fail to reach the specified acquisition criteria in either the self-administration or instrumental extinction phases of the experiment are removed from the study, and data is not included in final analysis.
Following instrumental extinction, re-exposure to cocaine-associated cues reinstates cocaine-seeking behavior, resulting in an increase in the number of active lever responses. This increase is observed in both groups of control experiments: rats that were injected with virus lacking oChIEF (AAV control) and rats that did not receive laser stimulation (SHAM control; Figure 3A) However, in vivo optogenetic LTD of MGN-LA terminals caused a reduction in subsequent cue-induced cocaine-seeking. 24 h following optogenetic LTD induction, the number of active lever presses was significantly reduced relative to both AAV controls and SHAM controls (Figure 3A). This low level of responding was maintained during a subsequent reinstatement test 7 days later (conducted in a subset of rats) (Figure 3B), indicating a persistent reduction in cue-motivated cocaine seeking across multiple reinstatement tests.
Ex vivo electrophysiological recordings from animals exposed to optical stimulation confirmed that the attenuation in reinstatement was indeed due at least in part to a modulation of MGN-LA synaptic plasticity. This was evidenced by a decrease in optically-evoked EPSC amplitude in LA neurons following exposure to optical LTD (Figure 4A). This attenuation in EPSC amplitude was specific to neurons that received optic stimulation, as EPSC amplitude remained unchanged in SHAM-controls. Additionally, LTD was unable to be generated in slices from rats that had already received in vivo optical stimulation, but was reliably evoked in neurons from rats that underwent SHAM stimulation, as evidenced by a sustained reduction in EPSP rise slope (Figure 4B). Thus, in vivo optical stimulation appears to occlude further LTD induction in slice. While recording, it is important to measure series resistance through the duration of the recording to ensure the maintained health of the patch. Cells with a change in series resistance beyond 20% are not accepted for data analysis. This is especially important for LTD experiments which last >60 min, as changes in series resistance can influence receptor and channel dynamics. To ensure that the afferents being stimulated during electrophysiological recordings originate in the MGN, it is important to collect slices through the extent of the thalamus. This serves as validation that the cell bodies of the MGN indeed fluorescently express AAV. In addition to visual confirmation, functional validation is also necessary. Under current-clamp conditions, AAV-oChIEF-infected MGN neurons fire action potentials in response to both high and low frequencies of 473-nm-light stimulation (Figure 4C).
All behavioral results were considered provisional until viral expression and optic fiber implants were histologically verified and proper placement was confirmed (Figure 5). Lack of AAV expression in either the MGN or LA and/or those in which the optic fibers were not correctly positioned within the dorsal LA were excluded from experimental analysis, but in some instances may be included as a negative anatomical control.
Figure 1: Timeline of experimental procedure. An outline of the critical steps of the protocol, including the sequential time course and duration of each experimental phase. Please click here to view a larger version of this figure.
Figure 2: Acquisition and extinction of cocaine self-administration. (A) Animals exhibit an increasing number of cocaine infusions and active lever responses across acquisition, and a low level of inactive lever responses. (B) Following an initial boost in lever pressing on day 1 of extinction, animals decrease responding on both active and inactive levers to a low, stable level. Error bars, mean ±SEM. This figure has been modified from Rich et al. 20194. Please click here to view a larger version of this figure.
Figure 3: In vivo optogenetic LTD attenuates cue-induced reinstatement. (A) Optical LTD causes a significant reduction in active lever presses during reinstatement relative to animals that received control virus or SHAM control stimulation. Two-way ANOVA, main effect of group (F(2,27) = 7.04, P = .004) and a day x group interaction (F(2,27) = 8.08, P = .002); Bonferroni's post hoc analysis: ***p < .001. (B) 7 days later, rats underwent a second reinstatement test, revealing a significant reduction in active lever pressing in animals that previously underwent MGN-LA LTD relative to SHAM controls. Two-way ANOVA, main effect of group (F(1,32) = 5.04, P = .032), significant interaction (F(1,32) = 7.69, P = .009); Bonferroni's post hoc analysis, **p < .01. Error bars, mean ±SEM, n in bars, number of rats. This figure has been modified from Rich et al. 20194. Please click here to view a larger version of this figure.
Figure 4: Functional validation of in vivo low-frequency optogenetic stimulation (A) In vivo dual hemisphere LTD of MGN-LA synapses attenuates EPSC amplitude relative to SHAM-controls (Unpaired t-test, t(10) = 2.73, *P = .021). Inset: Sample average EPSC traces evoked at Erev-70 mV. Scale bars: 50 ms, 200 pA, n in bars, number of rats (neurons). (B) In vivo optical LTD induction occludes ex vivo LTD. 24 h after in vivo LTD induction, amygdala slices were prepared and the same stimulation protocol was applied. EPSP rise slope at MGN-LA terminals was reduced by ex vivo optical stimulation in neurons from animals that had received in vivo SHAM stimulation, but not in neurons from animals that had received in vivo optical LTD. n in italics, number of neurons. (C) Sample current clamp recordings from AAV-oChIEF-infected MGN neurons. Action potentials were elicited by blue light stimulation (5-100 Hz). Scale bars: 100 ms, 40 mV. Error bars, mean ±SEM. This figure has been modified from Rich et al. 20194. Please click here to view a larger version of this figure.
Figure 5: Histological verification of viral expression and optic fiber placements. (A) Representative microscopic images showing DAPI and AAV-oChIEF-tdTomato expression in LA (Left) and MGN (Right). Scale bar: 2 mm. (B) Schematic showing injection of AAV-oChIEF-tdTomato and throughout the anterior-posterior extent of the LA (Left) and MGN (Right), and optic fiber placements in the LA. Dark red shading shows representation of smallest acceptable virus spread, and light pink shading shows representation of largest acceptable spread. Blue circles correspond to successful optic fiber placement in both hemispheres. Black circles correspond to successful optic fiber placement in only one hemisphere. Black "X" corresponds to unsuccessful fiber placement. To be included in final analysis, rats required viral dual hemisphere expression in the LA as well as successful placement of fibers. Coordinates are in mm, posterior from bregma. This figure has been modified from Rich et al. 20194. Please click here to view a larger version of this figure.
Chemical | mM | MW | g/1000 mL |
N-methyl-D-glucamine | 92 | 195.215 | 17.96 |
Potassium Chloride | 2.5 | 74.551 | 0.19 |
Sodium Phosphate Monobasic | 1.25 | 119.98 | 0.15 |
Sodium Bicarbonate | 30 | 84.01 | 2.52 |
HEPES | 20 | 238.301 | 4.77 |
D-glucose | 25 | 180.16 | 4.5 |
Sodium Ascorbate | 5 | 198.11 | 0.99 |
Thiourea | 2 | 76.12 | 0.15 |
Sodium Pyruvate | 3 | 110 | 0.33 |
Magnesium Sulfate | 10 | Use 5.0 mL of 2.0 M Stock | |
Calcium Chloride | 0.5 | Use 250 μL of 2.0 M Stock | |
1. For 1 L of solution, add salts in the order listed to 850 mL ddH2O | |||
2. pH with concentrated HCl to 7.3-7.4 (NMDG makes a basic solution) | |||
3. Oxygenate for 5-10 min then add MgSO4 and CaCl2 | |||
4. Bring final volutme to 1 L with ddH2O and double check final pH | |||
5. Check osmolarity with osmometer and adjust to 300-310 mOsm/kg H2O |
Table 1: List of Ingredients for Extracellular Cutting Solution. Ingredients and instructions used for the preparation of the NMDG-based extracellular cutting solution.
Chemical | mM | MW | g/1000 mL |
N-methyl-D-glucamine | 86 | 195.215 | 5.03 |
Potassium Chloride | 2.5 | 74.551 | 0.19 |
Sodium Phosphate Monobasic | 1.25 | 119.98 | 0.15 |
Sodium Bicarbonate | 35 | 84.01 | 2.94 |
HEPES | 20 | 238.301 | 4.77 |
D-glucose | 25 | 180.16 | 4.5 |
Sodium Ascorbate | 5 | 198.11 | 0.99 |
Thiourea | 2 | 76.12 | 0.15 |
Sodium Pyruvate | 3 | 110 | 0.33 |
Magnesium Sulfate | 1 | Use 500 μL of 2.0 M Stock | |
Calcium Chloride | 2 | Use 1000 μL of 2.0 M Stock | |
1. For 1 L of solution, add salts in the order listed to 850 mL ddH2O | |||
2. pH with 1 N HCl or KOH to 7.3-7.4 | |||
3. Oxygenate for 5-10 min then add MgSO4 and CaCl2 | |||
4. Bring final volutme to 1 L with ddH2O and double check final pH | |||
5. Check osmolarity with osmometer and adjust to 300-310 mOsm/kg H2O |
Table 2: List of Ingredients for Extracellular Holding Solution. Ingredients and instructions used for the preparation of the extracellular holding solution.
Chemical | mM | MW | g/1000 mL |
N-methyl-D-glucamine | 119 | 195.215 | 6.95 |
Potassium Chloride | 2.5 | 74.551 | 0.19 |
Sodium Phosphate Monobasic | 1.25 | 119.98 | 0.15 |
Sodium Bicarbonate | 26 | 84.01 | 2.18 |
HEPES | 5 | 238.301 | 1.19 |
D-glucose | 12.5 | 180.16 | 2.25 |
Magnesium Sulfate | 1 | Use 500 μL of 2.0 M Stock | |
Calcium Chloride | 2 | Use 1000 μL of 2.0 M Stock | |
1. For 1 L of solution, add salts in the order listed to 850 mL ddH2O | |||
2. pH with 1 N HCl or KOH to 7.3-7.4 | |||
3. Oxygenate for 5-10 min then add MgSO4 and CaCl2 | |||
4. Bring final volutme to 1 L with ddH2O and double check final pH | |||
5. Check osmolarity with osmometer and adjust to 300-310 mOsm/kg H2O |
Table 3: List of Ingredients for Extracellular Recording Solution. Ingredients and instructions used for the preparation of the extracellular recording solution.
Chemical | mM | MW | mg/50 mL |
Cesium Methanesulfonate | 108 | 227.997 | 1231.3 |
Cesium Chloride | 15 | 168.36 | 126.3 |
Cesium-EGTA | 0.4 | Add 80 μL of 250 mM Cs-EGTA | |
TEA-Chloride | 5 | 165.705 | 41.4 |
HEPES | 20 | 238.301 | 238.3 |
QX-314-Br | 1 | 343.31 | 17.2 |
L-glutathione | 1 | 307.323 | 15.4 |
Sodium Phosphocreatine | 7.5 | 255.1 | 95.7 |
Mg-ATP | 2.5 | 507.18 | 63.4 |
Na-GTP | 0.25 | 523.18 | 6.5 |
1. Start with 40-45 mL HPLC-grade H2O | |||
2. Keep phosphocreatine, ATP, and GTP on ice at all times. | |||
3. Add ingredients in the order listed in the table | |||
4. pH to 7.3 with CsOH (About 200 μL of 2 M CsOH) | |||
5. Use osmometer to check osmolarity. | |||
6. Add HPLC-grade H2O to a final osmolarity of about 285-290 mOsm/kg H2O | |||
7. Prepare 500-1000 μL aliquots and store at -80 °C or -20 °C |
Table 4: List of Ingredients for Cesium Methanesulfonate Intracellular Electrophysiology Solution. Ingredients and instructions used for the preparation of cesium methanesulfonate intracellular solution.
Chemical | mM | MW | mg/50 mL |
Potassium Gluconate | 145 | 234.246 | 1698.2 |
Potassium Chloride | 2.5 | 74.56 | 9.3 |
Sodium Chloride | 2.5 | 58.44 | 7.3 |
K-BAPTA | 0.1 | Add 80 μL of K-BAPTA | |
HEPES | 10 | 238.301 | 119.2 |
L-glutathione | 1 | 307.323 | 15.4 |
Sodium Phosphocreatine | 7.5 | 255.1 | 95.7 |
Mg-ATP | 2 | 507.18 | 63.4 |
Tris-GTP | 0.25 | 886.59 | 11.1 |
1. Start with 40-45 mL HPLC-grade H2O | |||
2. Keep phosphocreatine, ATP, and GTP on ice at all times. | |||
3. Add ingredients in the order listed in the table | |||
4. pH to 7.3 with KOH (About 200 μL of 2 M KOH) | |||
5. Use osmometer to check osmolarity. | |||
6. Add HPLC-grade H2O to a final osmolarity of about 285-290 mOsm/kg H2O | |||
7. Prepare 500-1000 μL aliquots and store at -80 °C or -20 °C |
Table 5: List of Ingredients for Potassium Gluconate Intracellular Electrophysiology Solution. Ingredients and instructions used for the preparation of potassium gluconate intracellular solution.
As described above, there are several critical steps that are important for achieving the proper experimental results. The protocol will likely only be effective in animals that properly acquire cocaine self-administration, and to date, it has only been tested using the parameters outlined above. It is possible that cocaine dose, schedule of reinforcement, and cue parameters can be modified with likely little effect on behavioral outcomes, with the exception that a second-order schedule of reinforcement may lead to amygdala-independent cocaine seeking that could reduce efficacy of the procedure, though this has not been directly tested14. There are several points throughout the protocol where validating proper construction and functioning of optic fibers, will help ensure successful optical stimulation. It is necessary to properly score ferrules to prevent loss from the headcap, and polish optic fibers, and to test that loss of light output through the implants does not exceed 30%9. Additionally, the laser stimulation parameters are important considerations. The laser should be operated at relatively low power (5-7 mW). Sustained, low frequency stimulation is used to induce LTD, and this can be functionally validated by measuring MGN-LA synaptic strength with electrophysiological recordings. Finally, results indicated a significant reduction in cue-induced reinstatement with a final n of 10 animals per group, however, experimenters should anticipate starting with a larger n, as it is likely that some animals will need to be excluded from final analysis. It is crucial to verify the proper anatomical placement and expression of virus and optical fibers, and to only use data from animals in which histology has been verified.
Despite the robust behavioral effect on cocaine-seeking observed with this protocol, there are several limitations that must be considered. For one, the method has only been tested in rats that were trained with a single audiovisual cue paired with cocaine. It's not clear what would happen in a scenario where multiple different cues were conditioned, which would be a more accurate representation of human addiction, whereby multiple environmental stimuli become highly associated with drug use15,16,17. Evidence from our lab indicates that the ability of optogenetic LTD to reduce drug-seeking is due to a decrease in synaptic strength that weakens drug-cue-associated memories. However, it is not clear to what extent neutral, or memories that are not associated with cocaine self-administration might be affected by this protocol. Furthermore, while the method only affects synaptic strength at one circuit, other circuits may also be important for encoding memory and/or driving cocaine seeking behavior18,19,20. Finally, it should be noted that LTD can only be induced at synapses where virus is sufficiently expressed, likely leaving some synaptic connections unaffected by the stimulation protocol, which potentially limits behavioral impact. Moreover, evidence suggests that only small ensembles of neurons and synapses are involved in the encoding of a particular memory, giving credence to the idea that LTD induction within an entire brain region is not the best strategy for effecting behavioral change, whereas other approaches exist to specifically target cue- or contextually-active populations of neurons21,22. Despite this, the protocol is effective at attenuating cue-motivated drug seeking, likely because the low-frequency optical stimulation limits LTD induction to synapses that have previously been potentiated by repeated cocaine-cue pairings4.
This protocol provides a significant advance to more commonly used optogenetic behavioral studies where the activity of neurons is activated or inhibited while the animal is performing the behavior in real-time19,23. Instead, optogenetics is used here as a neuromodulatory tool to reverse cocaine-induced plasticity. An advantage of this method is that the optogenetic manipulation is independent of the behavioral test, such that potential confounding effects of optogenetics (e.g., local circuit effects, refractory period after light stimulation, antidromic stimulation effects, etc.24 should not affect the results, thereby increasing confidence that the hypothesized neural mechanism is mediating changes in behavior. This method can therefore be utilized in a number of applications investigating how synaptic plasticity, particularly an increase in synaptic strength as occurs with LTP, relates to changes in behavior. Similar approaches might also be relevant to clinical application of neural stimulation technologies where abnormal connections in the brain driving dysfunctional behavior can be downregulated. Likewise, because the oChIEF viral construct is responsive to both low- and high-frequency stimulations, there are potential applications to these methods beyond the scope of the described experiments. For instance, optogenetically-induced LTP may be beneficial for reversing deficits in plasticity found in a wide range of neurodegenerative and neurodevelopmental disorders25. Furthermore, bidirectional plasticity at MGN-LA synapses has also been directly linked to the regulation of behaviors relevant to fear-associated disorders8.
Modulating the specific neural circuits that support drug-motivated behaviors is essential for establishing long-term abstinence from drug use. This protocol utilizes novel advances in in vivo optogenetics to reverse plasticity of a precise neural circuit that is strengthened by repeated cocaine self-administration in the presence of environmental cues. The result of this specific neuromodulation is a decreased likelihood for subsequent cue re-exposures to trigger a cocaine-seeking response, which may have important implications for the development of future therapies for substance use disorders.
The authors have nothing to disclose.
The authors wish to acknowledge support from USPHS grants K01DA031745 (MMT), R01DA042029 (MMT), DA035805 (YHH), F31DA039646 (MTR), T32031111 (MTR), and the Pennsylvania Department of Health.
0.9% Saline | Fisher Scientific | NC0291799 | |
A.M.P.I. Stimulus Isolator | Iso-Flex | ||
AAV5.hSyn.oChIEF.tdTomato | Duke Viral Vector Core (via Roger Tsien) | #268 | See Lin et al., 2009; Nabavi et al., 2014 |
AAV5.hSyn.tdTomato (Control) | Duke Viral Vector Core Control | See Lin et al., 2009; Nabavi et al., 2014 | |
Artificial Tears (Opthalmic Ointment) | Covetrus | 70349 | |
ATP Magnesium Salt | Fisher Scientific | A9187 | |
Betadine | Butler Schein | 38250 | |
Calcium chloride | Fisher Scientific | C1016 | |
Cesium chloride | Fisher Scientific | 289329 | |
Cesium hydroxide | Fisher Scientific | 516988 | |
Cesium methanesulfonate | Fisher Scientific | C1426 | |
Cocaine HCl | NIDA Drug Supply Center | 9041-001 | |
Cryostat | Leica | CM1950 | |
D-Glucose | Sigma-Aldrich | G8270 | |
DMSO | Fisher Scientific | BP231-1 | |
Dual-Channel Temperature Controller | Warner Instruments | TC-344C | |
EGTA | Fisher Scientific | E3889 | |
Ethanol | University of Pittsburgh Chemistry Stockroom | 200C5000 | |
Ferrule Dust Caps | Thor Labs | CAPL | White plastic dust caps for 1.25 mm Ferrules |
Ferrule Mating Sleeves | Doric Lenses | F210-3011 | Sleeve_BR_1.25, Bronze, 1.25 mm ID |
Ferrules | Precision Fiber Products | MM-FER2007C-2300 | Ø1.25 mm Multimode LC/PC Ceramic ferrule, Ø230 μm hole size |
Fiber Optic | Thor Labs | FP200URT | 200 μm core multimode fiber (0.5 NA) |
Fiber Optic Rotary Joint | Prizmatix | (Ordered from Amazon) | 18 mm diameter, FC-FC connector for fiber |
Fiber Stripping Tool | Thor Labs | T12S21 | |
Fluoroshield with DAPI | Sigma-Aldrich | F6057 | |
Gentamicin | Henry Schein | 6913 | |
GTP Sodium Salt | Fisher Scientific | G8877 | |
Hamilton syringe | Hamilton | 80085 | 10 μL volume, 26 gauge, 2 inch, point style 3 |
Heat Gun | Allied Electronics | 972-6966 | 250 V, 750-800 °F |
Heat-Curable Epoxy | Precision Fiber Products | PFP-353ND-8OZ | |
Heparin | Henry Schein | 55737 | |
HEPES | Sigma-Aldrich | H3375 | |
Hydrochloric Acid | Fisher Scientific | 219405490 | |
Isoflurane | Henry Schein | 29405 | |
Ketamine HCl | Henry Schein | 55853 | Ketamine is a controlled substance and should be handled according to institutional guidelines |
Lactated Ringer’s | Henry Schein | 9846 | |
Laser, driver, and laser-to-fiber coupler | OEM Laser Systems | BL-473-00100-CWM-SD-xx-LED-0 | 100 mW, 473-nm, diode-pumped solid-state laser (One option) |
L-glutathione | Fisher Scientific | G4251 | |
Lidocaine | Butler Schein | 14583 | |
Light Sensor | Thor Labs | PM100D | Compact energy meter console with digital display |
Loctite instant adhesive | Grainger | 5E207 | |
Magnesium sulfate | Sigma-Aldrich | 203726 | |
Microelectrode Amplifier/Data Acquisition | Molecular Devices | MULTICLAMP700B / Digidata 1440A | |
Microinjector pump | Harvard Apparatus | 70-4501 | Dual syringe |
Micromanipulator | Sutter Instruments | MPC-200/ROE-200 | |
Microscope | Olympus | BX51WI | Upright microscope for electrophysiology |
Microscope | Olympus | BX61VS | Epifluorescent slide-scanning microscope |
N-methyl-D-glucamine | Sigma-Aldrich | M2004 | |
Orthojet dental cement, liquid | Lang Dental | 1504BLK | black |
Orthojet dental cement, powder | Lang Dental | 1530BLK | Contemporary powder, black |
Paraformaldehyde | Sigma-Aldrich | P6148 | |
Patch Cables | Thor Labs | FP200ERT | Multimode, FT030 Tubing |
Picrotoxin | Fisher Scientific | AC131210010 | |
Polishing Disc | Thor Labs | D50FC | |
Polishing Pad | Thor Labs | NRS913 | 9" x 13" |
Polishing Paper | Thor Labs | LFG5P | 5 μm grit |
Polishing Paper | Thor Labs | LFG3P | 3 μm grit |
Polishing Paper | Thor Labs | LFG1P | 1 μm grit |
Polishing Paper | Thor Labs | LFG03P | 0.3 μm grit |
Potassium chloride | Sigma-Aldrich | P9333 | |
Potassium hydroxide | Fisher Scientific | P5958 | |
Potassium methanesulfonate | Fisher Scientific | 83000 | |
QX-314-Cl | Alomone Labs | Q-150 | |
Rimadyl (Carprofen) | Henry Schein | 24751 | |
Self-Administration Chambers/Software | Med Associates | MED-NP5L-D1 | |
Sodium bicarbonate | Sigma-Aldrich | S5761 | |
Sodium chloride | Sigma-Aldrich | S7653 | |
Sodium Hydroxide | Sigma-Aldrich | 1064980500 | |
Sodium L-Ascorbate | Sigma-Aldrich | A7631 | |
Sodium Pentobarbital | Henry Schein | 24352 | |
Sodium phosphate | Sigma-Aldrich | S9638 | |
Sodium phosphocreatine | Fisher Scientific | P7936 | |
Sodium pyruvate | Sigma-Aldrich | P2256 | |
Stainless steel machine screws | WW Grainger | 6GB25 | M2-0.40mm Machine Screw, Pan, Phillips, A2 Stainless Steel, Plain, 3 mm Length |
Stereotaxic adapter for ferrules | Thor Labs | XCL | |
Stereotaxic Frame | Stoelting | 51603 | |
Sucrose | Sigma-Aldrich | S8501 | |
Suture Thread | Fine Science Tools | 18020-50 | Silk thread; Size: 5/0, Diameter: 0.12 mm |
TEA-Chloride | Fisher Scientific | T2265 | |
Thiourea | Sigma-Aldrich | T8656 | |
Vetbond Tissue Adhesive | Covetrus | 001505 | |
Vibratome | Leica | VT1200S | |
Xylazine | Butler Schein | 33198 |